Patent Application
20070098798
The present invention is related to implantable medical devices and methods and, more particularly, to implantable medical devices and methods related to restoring function to the body of a patient.
Various organs of the body control the flow of bodily substances, including fluids, associated with that organ. Such organs may be located, for example, in the gastro-intestinal location, related to urinary or anal functions or in a vascular location. Examples of such locations include the upper esophageal sphincter, lower esophageal sphincter, pylorus, urinary sphincter and anal sphincter.
Any of such flow control organs may cease to function, or not function optimally, due, for example, to disease, injury and/or aging.
Lack of adequate flow control by such organs could result in discomfort, incontinence and even debilitation.
The present invention may allow the function of such flow control organ or organs to be restored.
In general, a biological agent may be administered to or near such flow control organ that can strengthen the tissue of the organ, enabling the organ to regain some or all of its function.
The biological agent can be stabilized at or near the location of the flow control organ to be treated. Being stabilized at or near the location of the organ, the biological agent may grow in-situ to replace or augment natural smooth muscle tissue of the organ that has been damaged or rendered non-responsive.
In an embodiment, the present invention provides a method of restoring function to a flow control location in a patient. A biological agent is inserted into a region near the flow control location. The biological agent is stabilized in the region. The biological agent is a biological agent selected from a group consisting of growth factors, fibroblast cells, smooth muscle cells, endothelial cells, stem cells and combinations thereof.
In an embodiment, the biological agent is injected into the region.
In an embodiment, the biological agent is associated with a carrier.
In another embodiment, the present invention provides an article intended to restore function to a flow control location in a patient. A carrier is adapted to be inserted into a region near the flow control location. A biological agent, associated with the carrier, selected from a group consisting of growth factors, fibroblast cells, smooth muscle cells, endothelial cells, stem cells and combinations thereof.
In an embodiment, the carrier is adapted to be inserted into tissue in the region.
In an embodiment, the carrier is a polymer matrix.
In an embodiment, the polymer matrix is a non-biodegradable polymer matrix.
In an embodiment, the polymer matrix is a biodegradable polymer matrix.
In an embodiment, the carrier is a hydrogel.
In an embodiment, the carrier is a dehydrated hydrogel.
In an embodiment, the hydrogel is allowed to hydrate following insertion.
In an embodiment, the region is selected from a group consisting of a gastro-intestinal location, a urinary location and a vascular location.
In an embodiment, the region is a location selected from the group consisting of an upper esophageal sphincter, lower esophageal sphincter, pylorus, urinary sphincter and anal sphincter.
In an embodiment, the biological agent is stabilized by placing the biological agent into tissue near the region.
In an embodiment, the tissue is muscle tissue.
Flow control organs in the body may be partially or fully restored to function with the stabilization of a biological agent at or near the location of the flow control organ. A flow control organ may be related the gastro-intestinal functions, urinary functions, anal functions or vascular functions. Examples of such flow control organs include the upper esophageal sphincter, lower esophageal sphincter, pylorus, urinary sphincter and anal sphincter.
The function of such a flow control organ may be partially or fully restored with the administration of a biological agent. Biological agents which may be utilized for this purpose include, but are not limited to, growth factors, fibroblast cells, smooth muscle cells, endothelial cells and stem cells, or combinations thereof.
As indicated in the flow chart of
The biological agent is then inserted (12) into a region near the location of the flow control organ. The location near the flow control organ may, in fact, be at the location or in the flow control organ itself. However, beneficial results may be obtained even if the insertion location is not actually the flow control organ but rather in a location nearby. By “nearby” it is meant a location in the vicinity of the flow control organ in which the biological agent provides therapeutic effect to the flow control organ. The exact nearness depends, at least in part, on the flow control organ to be restored. Insertion of the biological agent can be accomplished by any number of conventional insertion techniques such as, for example, endoscope.
Once the biological agent has been inserted, the biological agent is stabilized (14) at the desired location. Stabilization of the biological agent can be accomplished by any number of conventional techniques. Examples of stabilization techniques that can be used are described in U.S. Patent Application Publication No. 2005/0096497, Gerber et al, Implantable Devices and Methods For Treating Fecal Incontinence, and U.S. Patent Application Publication No. 2005/0096751, Gerber et al, Implantable Devices and Methods For Treating Urinary Incontinence. Other techniques that can be used are described in U.S. Pat. No. 6,754,536, Swoyer et al, Implantable Medical Device Affixed Internally Within the Gastrointestinal Tract; U.S. Pat. No. 6,952,613, Swoyer et al, Implantable Gastrointestinal Lead With Active Fixation; U.S. Patent Application Publication No. 2002/0103521, Implantable Gastrointestinal Lead With Active Fixation; and U.S. Patent Application Publication No. 2002/0103522, Swoyer et al, Implantable Bifurcated Gastrointestinal Lead With Active Fixation. The contents of all of these documents are hereby incorporated by reference in their entirety.
The biological agent is then associated (18) with a carrier. A carrier is a structure which acts to carry or harbor the biological agent and facilitate the delivery and stabilization of the biological agent to and in the location at or near the flow control organ.
Carrier 20 illustrated in
Biological agent 22 is associated with carrier 20 by, for example, saturating or impregnating carrier 20 with biological agent 22. Carrier 20 provides a physical carrier for biological agent 22 and allows biological agent 22 to be inserted into the body at the desired location at or near the flow control organ to be restored.
In a preferred embodiment illustrated in
Once biological agent 22 is associated (18 in
Biological agent 22 may be placed into tissue at the desired region by conventional means. In a preferred embodiment, biological agent 22 is placed in muscle tissue in such region.
The contents of co-pending application entitled “Method and Article to Restore Function to GI or Urinary Tract in a Patient” by inventor Warren L. Starkebaum (Attorney Docket No. 151P21313USO1), filed on even date herewith, is hereby incorporated by reference in its entirety.
Thus, embodiments of the method and article to restore function to a flow control location of a patient are disclosed. One skilled in the art will appreciate that the present invention can be practiced with embodiments other than those disclosed. The disclosed embodiments are presented for purposes of illustration and not limitation, and the present invention is limited only by the claims that follow.
This disclosure is related to the following co-pending application entitled “Method and Article to Restore Function to GI or Urinary Tract of a Patient” by inventor Warren L. Starkebaum (Attorney Docket No. 151P21313USO1), filed on even date herewith, which is not admitted as prior art with respect to the present disclosure by its mention in this section.
